- Home
- PGY vs IBRX Comparison
PGY vs IBRX Comparison
Compare PGY & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGY
- IBRX
- Stock Information
- Founded
- PGY 2016
- IBRX 2014
- Country
- PGY United States
- IBRX United States
- Employees
- PGY N/A
- IBRX N/A
- Industry
- PGY Finance: Consumer Services
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PGY Finance
- IBRX Health Care
- Exchange
- PGY Nasdaq
- IBRX Nasdaq
- Market Cap
- PGY 2.6B
- IBRX 2.3B
- IPO Year
- PGY N/A
- IBRX N/A
- Fundamental
- Price
- PGY $37.26
- IBRX $2.40
- Analyst Decision
- PGY Strong Buy
- IBRX Strong Buy
- Analyst Count
- PGY 8
- IBRX 5
- Target Price
- PGY $37.13
- IBRX $10.20
- AVG Volume (30 Days)
- PGY 3.9M
- IBRX 9.0M
- Earning Date
- PGY 08-07-2025
- IBRX 08-05-2025
- Dividend Yield
- PGY N/A
- IBRX N/A
- EPS Growth
- PGY N/A
- IBRX N/A
- EPS
- PGY N/A
- IBRX N/A
- Revenue
- PGY $1,153,015,000.00
- IBRX $56,600,000.00
- Revenue This Year
- PGY $27.97
- IBRX $629.94
- Revenue Next Year
- PGY $16.50
- IBRX $109.91
- P/E Ratio
- PGY N/A
- IBRX N/A
- Revenue Growth
- PGY 24.59
- IBRX 4227.22
- 52 Week Low
- PGY $8.20
- IBRX $1.83
- 52 Week High
- PGY $41.48
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- PGY 63.91
- IBRX 47.34
- Support Level
- PGY $34.76
- IBRX $2.29
- Resistance Level
- PGY $38.86
- IBRX $2.47
- Average True Range (ATR)
- PGY 2.56
- IBRX 0.12
- MACD
- PGY 0.14
- IBRX 0.02
- Stochastic Oscillator
- PGY 78.86
- IBRX 60.53
About PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.